Advanced Malignant Solid Tumors Clinical Trial
Official title:
Phase I Multicenter, Open-label, Dose-escalating Clinical and Pharmacokinetic Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors
Phase I multicenter, open-label, dose-escalating clinical and pharmacokinetic trial of PM02734 administered in combination with erlotinib to determine the safety and tolerability and to identify the dose limiting toxicity (DLT) and the recommended dose (RD) of the combination of PM02734 and erlotinib, in patients with advanced malignant solid tumors.
Phase I multicenter, open-label, dose-escalating clinical and pharmacokinetic trial of PM02734 administered in combination with erlotinib to determine the safety and tolerability and to identify the dose limiting toxicity (DLT) and the recommended dose (RD) of the combination of PM02734 and erlotinib, determine the preliminary pharmacokinetics (PK) of the combination, evaluate the preliminary PK/pharmacodynamic correlation, evaluate the preliminary antitumor activity, perform a preliminary pharmacogenomic (PGx) study to explore molecular predictors of response to ErbB receptor antagonists and PM02734 in patient with advanced malignant solid tumors. ;
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00728468 -
A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer Patients
|
Phase 1 | |
| Completed |
NCT00445458 -
A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT00768469 -
Study Evaluating Safety And Tolerability, Solid Tumor
|
Phase 1 | |
| Recruiting |
NCT04226066 -
Safety, Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC), in Patients With Advanced Malignant Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04908046 -
A Study of HMPL-295S1 in Patients With Advanced Malignant Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT06464055 -
A Study of GQ1010 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06231550 -
A Study of Axl Inhibitor FC084CSA in Patients With Advanced Malignant Solid Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT05383703 -
Clinical Study of MNC-168 Enteric-coated Capsule in the Treatment of Advanced Intestinal Solid Tumor
|
Phase 1 | |
| Recruiting |
NCT05773937 -
A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors
|
Phase 1 | |
| Completed |
NCT04328506 -
Bioequivalency Study of CM082 Tablet in Healthy Volunteers
|
Phase 1 | |
| Recruiting |
NCT05886374 -
A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors
|
Phase 1 | |
| Completed |
NCT00958724 -
Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT05949775 -
Clinical Study of mRNA Vaccine in Patients With Advanced Malignant Solid Tumors
|
N/A | |
| Terminated |
NCT02045095 -
A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05277454 -
Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT
|
Phase 1 | |
| Active, not recruiting |
NCT03792958 -
Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid Tumors
|
Phase 1 | |
| Withdrawn |
NCT00997360 -
Study of PKI-179 Administered Orally to Subjects With Solid Tumors
|
Phase 1 | |
| Completed |
NCT04126668 -
A Study to Investigate the Food Effect on the Pharmacokinetics of CM082 Tablet in Chinese Healthy Volunteers
|
Phase 1 | |
| Recruiting |
NCT05338957 -
A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors.
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03047811 -
The Study of Targeted NY-ESO-1 T Cell Receptor (TCR) Genetic Modified Autologous T Cells Treatment of Advanced Solid Tumors
|
N/A |